Abstract/Journal Article DZNE-2025-01470

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Amyloid‐induced neuronal hyperactivity and ‐metabolism are associated with faster tau accumulation in Alzheimer's Disease

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025

Alzheimer’s Association International Conference, AAIC 25, TorontoToronto, Canada, 27 Jul 2025 - 31 Jul 20252025-07-272025-07-31 Alzheimer's and dementia 21(Suppl 2), e099685 () [10.1002/alz70856_099685]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: The link between amyloid (Aβ) and tau accumulation in Alzheimer's disease (AD) is still unknown, hindering therapeutic efforts to attenuate the Aβ-tau axis. Preclinical studies demonstrated that Aβ promotes hyperexcitatory neuronal activity and that tau spreads trans-synaptically in an activity-dependent manner. We recently showed that tau spreads across connected brain regions, and that Aβ-related connectivity increases promote tau spreading (Roemer-Cassiano et al., 2024). Yet, it is unclear whether Aβ-related hyperconnectivity indeed represents hyperexcitatory neuronal activity. To test this, we combined resting-state fMRI, FDG-PET and post-mortem data, to determine whether Aβ promotes neuronal hyperactivity, thereby driving tau spread in AD.We first assessed the effect Aβ on neuronal hyperactivity with a novel algorithm to estimate the excitatory to inhibitory (E/I) ratio applied to resting-state fMRI in 145 amyloid-negative controls and 441 amyloid-positive subjects across the AD spectrum, who also underwent amyloid-PET. Second, we used glucose metabolism (FDG-PET) as a marker of neuronal activity in 638 amyloid-positive AD spectrum patients, with a subset (n = 215) of them having tau-PET at a later timepoint. Lastly, we analysed post-mortem data of 5 AD patients and 4 controls stained for c-Fos as a marker of ante-mortem neuronal activity.Resting-state fMRI-based E/I-ratio assessment in Aβ- controls showed biologically plausible stronger inhibition in association cortices (Figure 1A). In AD, we found an association between higher amyloid-PET SUVRs and a higher E/I ratio, consistent across diagnostic groups (Figure 1B-D), indicative of Aβ-associated hyperexcitatory neuronal activity. Second, we found within individuals, that higher regional amyloid-PET was linked to higher FDG-PET (correlationamyloid-PET vs. FDG-PET: 95% CI [0.37,0.40] p-value <0.001), suggesting higher neuronal activity in Aβ-harbouring regions (Figure 2A). Similarly, we found post-mortem elevated neuronal c-Fos expression in AD brain tissue vs. controls, indicating higher ante-mortem neuronal activity (Figure 3G). Finally, we found that amyloid-PET-based prediction of subject-level future tau accumulation is improved when including regional FDG-PET (Figure 2B) and that FDG-PET-assessed hypermetabolism mediates subject-level effects of Aβ on subsequent tau accumulation (Figure 2C).Aβ promotes an hyper-excitatory shift in neuronal activity that manifests in glucose hypermetabolism which promotes Aβ-related tau accumulation. Thus, Aβ-associated neuronal hyper-excitability is a potential target for attenuating the Ab-tau axis in AD.

Keyword(s): Humans (MeSH) ; Alzheimer Disease: metabolism (MeSH) ; Alzheimer Disease: diagnostic imaging (MeSH) ; Alzheimer Disease: pathology (MeSH) ; Positron-Emission Tomography (MeSH) ; Female (MeSH) ; Male (MeSH) ; Biomarkers: metabolism (MeSH) ; Magnetic Resonance Imaging (MeSH) ; Aged (MeSH) ; tau Proteins: metabolism (MeSH) ; Amyloid beta-Peptides: metabolism (MeSH) ; Brain: metabolism (MeSH) ; Brain: diagnostic imaging (MeSH) ; Brain: pathology (MeSH) ; Fluorodeoxyglucose F18 (MeSH) ; Neurons: metabolism (MeSH) ; Aged, 80 and over (MeSH) ; Biomarkers ; tau Proteins ; Amyloid beta-Peptides ; Fluorodeoxyglucose F18

Classification:

Contributing Institute(s):
  1. Molecular Neurobiology (AG Simons)
  2. Vascular Cognitive Impairment & Post-Stroke Dementia (AG Dichgans)
  3. Clinical Research (Munich) (Clinical Research (Munich))
  4. Molecular Neurodegeneration (AG Haass)
Research Program(s):
  1. 351 - Brain Function (POF4-351) (POF4-351)
  2. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
  3. 352 - Disease Mechanisms (POF4-352) (POF4-352)

Appears in the scientific report 2025
Database coverage:
Medline ; Creative Commons Attribution CC BY 4.0 ; OpenAccess ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Institute Collections > M DZNE > M DZNE-Clinical Research (Munich)
Document types > Articles > Journal Article
Document types > Presentations > Abstracts
Institute Collections > M DZNE > M DZNE-AG Dichgans
Institute Collections > M DZNE > M DZNE-AG Simons
Institute Collections > M DZNE > M DZNE-AG Haass
Full Text Collection
Public records
Publications Database

 Record created 2025-12-29, last modified 2025-12-30


OpenAccess:
Download fulltext PDF Download fulltext PDF (PDFA)
External link:
Download fulltextFulltext by Pubmed Central
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)